Physician profile
Heather Wheeler
NPI 1124388293
$3,095.98
in general payments reported to CMS, 2019-2025
27 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $137 · 2021: $433 · 2022: $281 · 2023: $532 · 2024: $418 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,466.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.17 | 2020-2025 | Vraylar, Qulipta, Linzess |
| Pfizer INC. | $693.75 | 2019-2025 | |
| Astellas Pharma US INC | $206.92 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $183.17 | 2019-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $161.51 | 2019-2021 | |
| Novo Nordisk INC | $142.94 | 2019-2024 | Wegovy |
| Merck Sharp & Dohme LLC | $108.75 | 2019-2022 | |
| Glaxosmithkline, LLC. | $86.98 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $86.94 | 2019-2025 | Otezla, Repatha |
| Amarin Pharma, INC. | $82.15 | 2019-2021 | |
| Shield Therapeutics INC | $78.29 | 2025 | |
| Dexcom, INC. | $76.59 | 2022-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.30 | 2019-2023 | Xifaxan |
| Organon LLC | $44.00 | 2025 | Nexplanon |
| Lilly USA, LLC | $36.86 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $34.54 | 2020 | |
| Allergan, INC. | $34.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.45 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $28.44 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $24.66 | 2025 | Monoferric |
| Sanofi-Aventis U.S. LLC | $23.99 | 2021 | |
| Dynavax Technologies Corporation | $21.97 | 2024 | Heplisav-B |
| Sunovion Pharmaceuticals INC. | $18.52 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.76 | 2022 | |
| Sanofi Pasteur INC. | $15.31 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $12.37 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.